← Back to all signals
RESEARCH PAPER ANALYSIS

Self-Controlled Feedback on Motor Learning and Neuroplastic Changes in People With Parkinson Disease.

This randomized yoked-controlled study found that self-controlled feedback during a finger-press trajectory task improved 7-day motor retention and was associated with increased corticomotor excitability in people with Parkinson disease compared with yoked feedback.

PMID41992310
JournalJournal of neurologic physical therapy : JNPT
Publication Date2026-04-14
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This randomized yoked-controlled study found that self-controlled feedback during a finger-press trajectory task improved 7-day motor retention and was associated with increased corticomotor excitability in people with Parkinson disease compared with yoked feedback.

WHY IT MATTERS

Research significance

The paper identifies a simple, implementable rehabilitation strategy that enhances motor learning and a neurophysiological marker of plasticity in PD, offering actionable guidance for clinical therapy design though it does not address disease-modifying mechanisms.

ABSTRACT

Source abstract

BACKGROUND AND PURPOSE: People with Parkinson disease (PD) experience impaired motor learning. Although numerous studies have shown that self-controlled feedback can facilitate motor learning in healthy young adults, whether similar benefits can be observed in people with PD has been less investigated. This study thus aimed to examine whether self-controlled feedback could benefit motor learning for individuals with PD, and to determine the associated behavioral and neurophysiological mechanisms. METHODS: Thirty-two participants with PD, matched in pairs, were recruited into a self-control group (SELF) and a yoked group (YOKE) to practice a finger-pressing trajectory-matching task. All participants visited the laboratory on day 1 (D1) and day 2 (D2) to practice the trajectory-matching task. The SELF group could decide when to receive feedback, whereas the YOKE group received feedback based on their counterparts' choices. Retention tests were performed on D2 after practice and on day 7 (D7). Additionally, motivation questionnaires, error estimation ability, and corticomotor excitability were examined. RESULTS: Both groups showed improvements in the trajectory-matching task throughout practice. On D7, the SELF group retained its trajectory-matching task performance and showed an increase in corticomotor excitability, whereas these changes were not observed in the YOKE group. There were no significant group differences in the motivation questionnaire or error estimation results. DISCUSSION AND CONCLUSIONS: Self-controlled feedback facilitated motor learning accompanied by increased corticomotor excitability in people with PD. Clinicians may consider incorporating self-control practices into the PD rehabilitation regimen to enhance training benefits. CLINICALTRIALGOV ID: NCT05960331.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic